Eli Lilly and Co

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
43K
Market Cap
$859.4B
Website
Introduction

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.

Phase 2
Completed
Conditions
First Posted Date
2005-09-19
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
43
Registration Number
NCT00191711
Locations
๐Ÿ‡ฎ๐Ÿ‡น

For additional information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your physician, Sesto Fiorentino, Florence, Italy

A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain

Phase 3
Completed
Conditions
First Posted Date
2005-09-19
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
310
Registration Number
NCT00191919
Locations
๐Ÿ‡ธ๐Ÿ‡ฐ

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rimavaska Sobota, Slovakia

Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence

Phase 2
Completed
Conditions
First Posted Date
2005-09-19
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
200
Registration Number
NCT00190606
Locations
๐Ÿ‡ณ๐Ÿ‡ฑ

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Nieuwegein, Netherlands

Raloxifene Use for The Heart

Phase 3
Completed
Conditions
First Posted Date
2005-09-19
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
10000
Registration Number
NCT00190593
Locations
๐Ÿ‡บ๐Ÿ‡ธ

For additonal information regarding investigative sites for this trial, please call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Monday-Friday, 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Minneapolis, Minnesota, United States

A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma

Phase 2
Completed
Conditions
First Posted Date
2005-09-19
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
43
Registration Number
NCT00192088
Locations
๐Ÿ‡ฎ๐Ÿ‡น

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-371-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Verona, Italy

A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

First Posted Date
2005-09-19
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
162
Registration Number
NCT00191607
Locations
๐Ÿ‡บ๐Ÿ‡ธ

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Louis, Missouri, United States

A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme

Phase 4
Completed
Conditions
First Posted Date
2005-09-19
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
60
Registration Number
NCT00191828
Locations
๐Ÿ‡ฎ๐Ÿ‡น

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speack with your personal physician., Sesto Fiorentino, Florence, Italy

To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence

Phase 3
Completed
Conditions
First Posted Date
2005-09-19
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
600
Registration Number
NCT00190645
Locations
๐Ÿ‡บ๐Ÿ‡ธ

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Denver, Colorado, United States

๐Ÿ‡จ๐Ÿ‡ฆ

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559,1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Oakville, Ontario, Canada

A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer

Phase 2
Completed
Conditions
First Posted Date
2005-09-19
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
30
Registration Number
NCT00191347
Locations
๐Ÿ‡จ๐Ÿ‡ฆ

For additional information regarding investigative sites for thsi trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada

Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

First Posted Date
2005-09-19
Last Posted Date
2007-01-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
200
Registration Number
NCT00191633
Locations
๐Ÿ‡จ๐Ÿ‡ฆ

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Summerside, Prince Edward Island, Canada

๐Ÿ‡จ๐Ÿ‡ฆ

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saskatoon, Saskatchewan, Canada

ยฉ Copyright 2024. All Rights Reserved by MedPath